Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $399.4 down -5.47% from its previous closing price of $422.5. In other words, the price has decreased by -$5.47 from its previous closing price. On the day, 1.4 million shares were traded. ALNY stock price reached its highest trading level at $425.19 during the session, while it also had its lowest trading level at $393.48.
Ratios:
For a deeper understanding of Alnylam Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 238.37. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
Oppenheimer Upgraded its Perform to Outperform on August 04, 2025, while the target price for the stock was maintained at $490.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when Fitzgerald Kevin Joseph sold 12,128 shares for $452.18 per share. The transaction valued at 5,483,990 led to the insider holds 21,264 shares of the business.
Fitzgerald Kevin Joseph bought 12,128 shares of ALNY for $5,445,472 on Nov 17 ’25. On Nov 12 ’25, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 15,650 shares for $453.69 each. As a result, the insider received 7,100,322 and left with 65,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 52766257152 and an Enterprise Value of 52814942208. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1661.40, and their Forward P/E ratio for the next fiscal year is 52.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.44 while its Price-to-Book (P/B) ratio in mrq is 225.05. Its current Enterprise Value per Revenue stands at 16.453 whereas that against EBITDA is 164.522.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.35, which has changed by 0.7753593 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -7.07%, while the 200-Day Moving Average is calculated to be 6.61%.
Shares Statistics:
For the past three months, ALNY has traded an average of 1.27M shares per day and 837750 over the past ten days. A total of 131.79M shares are outstanding, with a floating share count of 129.79M. Insiders hold about 1.76% of the company’s shares, while institutions hold 99.43% stake in the company. Shares short for ALNY as of 1765756800 were 4184652 with a Short Ratio of 3.28, compared to 1763078400 on 4279250. Therefore, it implies a Short% of Shares Outstanding of 4184652 and a Short% of Float of 4.16.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Alnylam Pharmaceuticals Inc (ALNY).The consensus estimate for the next quarter is $2.32, with high estimates of $2.74 and low estimates of $1.82.
Analysts are recommending an EPS of between $5.99 and $2.57 for the fiscal current year, implying an average EPS of $4.82. EPS for the following year is $10.74, with 13.0 analysts recommending between $18.05 and $5.55.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $1.18B this quarter.It ranges from a high estimate of $1.61B to a low estimate of $1.07B. As of . The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 21 analysts are estimating revenue of $1.24B. There is a high estimate of $1.45B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 25 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.5B, resulting in an average revenue estimate of $3.76B. In the same quarter a year ago, actual revenue was $2.25BBased on 24 analysts’ estimates, the company’s revenue will be $5.41B in the next fiscal year. The high estimate is $7.36B and the low estimate is $4.34B.
